[go: up one dir, main page]

WO2016039620A3 - Virosomes du virus respiratoire syncytial - Google Patents

Virosomes du virus respiratoire syncytial Download PDF

Info

Publication number
WO2016039620A3
WO2016039620A3 PCT/NL2014/050628 NL2014050628W WO2016039620A3 WO 2016039620 A3 WO2016039620 A3 WO 2016039620A3 NL 2014050628 W NL2014050628 W NL 2014050628W WO 2016039620 A3 WO2016039620 A3 WO 2016039620A3
Authority
WO
WIPO (PCT)
Prior art keywords
synthetic
respiratory syncytial
syncytial virus
virosomes
phad
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/NL2014/050628
Other languages
English (en)
Other versions
WO2016039620A2 (fr
Inventor
Antonius Johannes Henrikus STEGMANN
Joan Claudia Maureen SOEI-KEN TJON
Farien Irasia BHOELAN
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bestewil Holding BV
Original Assignee
Bestewil Holding BV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bestewil Holding BV filed Critical Bestewil Holding BV
Priority to PCT/NL2014/050628 priority Critical patent/WO2016039620A2/fr
Publication of WO2016039620A2 publication Critical patent/WO2016039620A2/fr
Publication of WO2016039620A3 publication Critical patent/WO2016039620A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
    • C12N2760/18523—Virus like particles [VLP]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
    • C12N2760/18534—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

La présente invention concerne le domaine de l'immunologie et de la vaccinologie, en particulier les virosomes du virus respiratoire syncytial (VRS), et des vaccins les comprenant. L'invention porte plus particulièrement sur un virosome du VRS comprenant les éléments suivants : (i) des lipides et des protéines extraites de la membrane du virus respiratoire syncytial ; (ii) un adjuvant synthétique choisi parmi le PHAD (disaccharide hexa-acylé phosphorylé) et son dérivé 3-O-désacyle, 3-D-PHAD ; (iii) au moins une espèce synthétique ou sensiblement pure de phosphatidylcholine et au moins une phosphatidyléthanolamine synthétique ou sensiblement pure dans un rapport molaire de 3/1 à 1/3, caractérisées en ce que les chaînes acyles comportent entre 4 et 18 atomes de carbone, le nombre total de liaisons insaturées dans les chaînes acyle étant de quatre, et le rapport molaire du phospholipide synthétique totale par rapport à l'adjuvant étant compris entre 1,5 et 10 ; (iv) un stérol ou un dérivé de stérol dans un rapport de 0 à 30 % en mole du phospholipide total ajouté ; et v) éventuellement un ou plusieurs antigènes.
PCT/NL2014/050628 2014-09-12 2014-09-12 Virosomes du virus respiratoire syncytial Ceased WO2016039620A2 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
PCT/NL2014/050628 WO2016039620A2 (fr) 2014-09-12 2014-09-12 Virosomes du virus respiratoire syncytial

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/NL2014/050628 WO2016039620A2 (fr) 2014-09-12 2014-09-12 Virosomes du virus respiratoire syncytial

Publications (2)

Publication Number Publication Date
WO2016039620A2 WO2016039620A2 (fr) 2016-03-17
WO2016039620A3 true WO2016039620A3 (fr) 2016-06-09

Family

ID=51660580

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/NL2014/050628 Ceased WO2016039620A2 (fr) 2014-09-12 2014-09-12 Virosomes du virus respiratoire syncytial

Country Status (1)

Country Link
WO (1) WO2016039620A2 (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11523988B2 (en) 2018-11-29 2022-12-13 Catalent U.K. Swindon Zydis Limited Oral dispersible vaccine comprising virosomes
EP4004036A4 (fr) * 2019-07-30 2023-11-15 Verndari, Inc. Vaccins à particules de type virus

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005117958A1 (fr) * 2004-05-28 2005-12-15 Glaxosmithkline Biologicals S.A. Compositions de vaccin comprenant des virosomes et un adjuvant a base de saponine
EP2058002A1 (fr) * 2007-10-31 2009-05-13 Bestewil Holding B.V. Membranes reconstituées du virus respiratoire syncytial et utilisation en tant que vaccin contre le virus respiratoire syncytial

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4912094B1 (en) 1988-06-29 1994-02-15 Ribi Immunochem Research Inc. Modified lipopolysaccharides and process of preparation
EP1447080A1 (fr) 2003-02-13 2004-08-18 Bestewil Holding B.V. Procéde de production de particules de type virosome
AR056245A1 (es) 2003-06-19 2007-10-03 Bestewil Holding Bv Membranas virales reconstituidas funcionales que contienen un coadyuvante

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005117958A1 (fr) * 2004-05-28 2005-12-15 Glaxosmithkline Biologicals S.A. Compositions de vaccin comprenant des virosomes et un adjuvant a base de saponine
EP2058002A1 (fr) * 2007-10-31 2009-05-13 Bestewil Holding B.V. Membranes reconstituées du virus respiratoire syncytial et utilisation en tant que vaccin contre le virus respiratoire syncytial

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
STEGMANN T ET AL: "FUNCTIONAL RECONSTITUTION OF INFLUENZA VIRUS ENVELOPES", EMBO JOURNAL, OXFORD UNIVERSITY PRESS, SURREY, GB, vol. 6, no. 9, 1 January 1987 (1987-01-01), pages 2651 - 2660, XP009020387, ISSN: 0261-4189 *
TOBIAS KAMPHUIS ET AL: "Immunogenicity and Protective Capacity of a Virosomal Respiratory Syncytial Virus Vaccine Adjuvanted with Monophosphoryl Lipid A in Mice", PLOS ONE, vol. 7, no. 5, 9 May 2012 (2012-05-09), pages e36812, XP055188434, DOI: 10.1371/journal.pone.0036812 *
TOON STEGMANN ET AL: "Lipopeptide-adjuvanted respiratory syncytial virus virosomes: A safe and immunogenic non-replicating vaccine formulation", VACCINE, vol. 28, no. 34, 1 August 2010 (2010-08-01), pages 5543 - 5550, XP055188433, ISSN: 0264-410X, DOI: 10.1016/j.vaccine.2010.06.041 *

Also Published As

Publication number Publication date
WO2016039620A2 (fr) 2016-03-17

Similar Documents

Publication Publication Date Title
MY184381A (en) Stable formulations of lipids and liposomes
WO2015130584A3 (fr) Adjuvants de vaccins sous forme de nanoparticules lipidiques et systèmes d'administration d'antigènes
EP4501318A3 (fr) Vaccins d'acides nucléiques
PH12018500856A1 (en) Respiratory syncytial virus vaccine
WO2017070620A3 (fr) Vaccin contre le virus de la grippe à large spectre
EP4588521A3 (fr) Conjugués polypeptide-antigène avec des acides aminés non naturels
UY31942A (es) Formulaciones de adyuvante comprendiendo combinaciones de triterpenoides, esteroles, inmunomoduladores, polímeros y estimuladores de th2, procedimientos de preparación, composiciones y aplicaciones.
AU2015261096A8 (en) Process for preparing phosphorus-containing cyanohydrins
WO2014179748A3 (fr) Compositions et procédés d'obtention de lipide fongique
MX375274B (es) Vacuna contra la acinetobacter baumannii obtenida a partir de componentes celulares carentes de lipopolisacarido.
BR112017017310A2 (pt) composições lipídicas
MX2018014086A (es) Formulacion que contiene agonista tlr y metodos de uso.
WO2016062020A9 (fr) Composants et principes actifs du pachyme, leur procédé de préparation et leur utilisation
WO2016077832A3 (fr) Procédés et intermédiaires pour préparer des éthers de dialcane à terminaison α,ω-acide dicarboxylique
EP3502119A3 (fr) Beta-1,6-d-glucanes immunomodulateurs
WO2016039620A3 (fr) Virosomes du virus respiratoire syncytial
PH12014502223A1 (en) Outer membrane proteins of histophilus somni and methods thereof
UY33208A (es) Composiciones que comprenden productos de azúcar cisteína
WO2009060305A3 (fr) Analogues de glycolipides en tant qu'immunoadjuvants
WO2014145839A3 (fr) Adjuvants de vaccins liposomaux et procédés de traitement et de fabrication de ceux-ci
BR112019011286A2 (pt) métodos para produzir uma composição de lipossoma, para preparar uma composição de vacina e para preparar um kit de vacina.
AR093530A1 (es) Adyuvante de vacunacion, preparacion, y vacunas que lo contienen
WO2012103444A3 (fr) Compositions et réactifs immunogènes pour une préparation
EA201291449A1 (ru) Вакцинная композиция на основе стихолизина, инкапсулированного в липосомы
WO2015197860A3 (fr) Nouveaux analogues de thapsigargine et leurs procédés de préparation

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 14780910

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 14780910

Country of ref document: EP

Kind code of ref document: A2